Postprandial administration but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia

Bong Lee, Jong, Zang, Xiaowei, Zgair, Atheer, Qian Ooi, Ting, Foley, David W ORCID: https://orcid.org/0000-0001-8449-4754, Voronin, Gregory, Kagan, Leonid, Soukarieh, Fadi, Gao, Rui, Shao, Hao, Tying Soh, Wan, Hwan Kim, Tae, Gi Kim, Min, Yun, Hwi-yeol, Wilson, Anthony J., Fischer, Peter M. and Gershkovich, Pavel 2021. Postprandial administration but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia. European Journal of Pharmaceutics and Biopharmaceutics 165 , pp. 106-112. 10.1016/j.ejpb.2021.05.006

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (393kB) | Preview

Abstract

For treatment of chronic cancers, the oral administration route is preferred as it provides numerous advantages over other delivery routes. However, these benefits of oral chemotherapy can be limited due to unfavorable pharmacokinetics. Accordingly, pharmacokinetic development of chemotherapeutic agents is crucial to the improvement of cancer treatment. In this study, assessment and optimization of biopharmaceutical properties of a promising drug candidate for cyclin-dependent kinase 9 (CDK9) inhibitor (DF030263) was performed to promote oral delivery. Oral bioavailability of DF030263 in fasted rats was 23.8%, and a distinct double-peak phenomenon was observed. A two-site absorption windows mechanism was proposed as a possible explanation to the phenomenon. The two-site absorption window hypothesis was supported by in vitro solubility assays in biorelevant fluids with different pH levels, as well as by in silico simulation by GastroPlusTM. Controlled release to the colon was conducted in rats in order to exploit the colonic absorption window but did not improve the oral bioavailability. On the other hand, oral administration at postprandial conditions in rats (performed based on the high in vitro solubility in fed state simulated fluid and reduced pH-dependency) resulted in an almost 3-fold increase in bioavailability to 63.6%. In conclusion, this study demonstrates an efficient in vitro-in vivo-in silico drug development approach for improving the oral bioavailability of DF030263, a promising candidate for the treatment of chronic lymphocytic leukemia.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Publisher:	Elsevier
ISSN:	0939-6411
Date of First Compliant Deposit:	17 May 2021
Date of Acceptance:	4 May 2021
Last Modified:	09 May 2023 11:56
URI:	https://orca.cardiff.ac.uk/id/eprint/141387

Actions (repository staff only)

Edit Item